Related Experiment Video
Updated: Jun 8, 2026
11:27
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
Everolimus in renal cell carcinoma
1International Biomedical Communications, Frederick, MD, USA. Dr.Yanni.Wang@gmail.com
Drugs of Today (Barcelona, Spain : 1998)
|September 11, 2010
Summary
Everolimus (RAD-001) is an effective treatment for advanced renal cell carcinoma (RCC) that has progressed on other therapies. This oral medication demonstrated good tolerability and improved progression-free survival rates in patients with advanced RCC.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced renal cell carcinoma (RCC) presents a significant therapeutic challenge.
- Prior treatments like sunitinib and sorafenib may not be effective for all patients.
- Mammalian target of rapamycin (mTOR) pathway inhibitors offer a novel therapeutic approach.
Purpose of the Study:
- To evaluate the efficacy and safety of everolimus in patients with advanced RCC.
- To determine the progression-free survival (PFS) rates associated with everolimus treatment.
- To identify the most common adverse events in patients receiving everolimus.
Main Methods:
- A randomized phase III clinical trial was conducted.
- Patients received 10 mg of everolimus daily.
- Disease progression was assessed based on predefined criteria.
Main Results:
- Everolimus demonstrated a 36% 6-month PFS rate and a 31% 3-month PFS rate.
- The treatment was generally well-tolerated, with most adverse events being mild to moderate.
- Frequent grade 3-4 adverse events included stomatitis, fatigue, pneumonitis, and infections.
Conclusions:
- Everolimus is an effective and well-tolerated treatment option for advanced RCC patients progressing on prior therapies.
- The drug offers a meaningful improvement in progression-free survival.
- Ongoing trials are exploring combination therapies involving everolimus for RCC treatment.
More Related Videos
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
07:50Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
Published on: May 25, 2018
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Renal Drug Excretion: Overview
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
01:25Renal Drug Excretion: Tubular Reabsorption
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...